# A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants

> **NCT05217641** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 108 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** BG505 MD39.3 mRNA
- **BIOLOGICAL:** BG505 MD39.3 gp151 mRNA
- **BIOLOGICAL:** BG505 MD39.3 gp151 CD4KO mRNA

## Key facts

- **NCT ID:** NCT05217641
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-11
- **Primary completion:** 2023-07-17
- **Final completion:** 2027-06-24
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2025-10-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05217641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05217641, "A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05217641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*